Matt collaborates with late R&D and early commercial teams to develop and commercialize new oncology medicines, with a focus on emerging targets and new modalities.

Matt joined ZS in 2014 and is a lead within the ZS oncology and advanced therapeutics practice areas. He leads oncology engagements in portfolio and pipeline strategy, commercial strategy, market research, forecasting and secondary data analytics.

Matt’s expertise spans solid tumors and hematological malignancies, with a particular focus on the intersection of therapeutic targets, modalities and tumor types. Matt has expertise with cell therapies, targeted radiopharmaceuticals, antibody drug conjugates and multispecific antibodies. In addition to advising his clients on the development and commercialization of novel oncology therapeutics, Matt has attended oncology medical congresses on behalf of the ZS oncology practice area. Matt also publishes external thought leadership on oncology development and commercialization topics.

Before joining ZS, Matt worked with a boutique healthcare consulting firm, focused primarily on the cardiovascular and oncology spaces. Prior to consulting, he studied the impact of diet on the biophysics of neutrophil cell membranes.

Matt holds a Ph.D. in bioengineering from the University of Pennsylvania. He also holds a B.S.E. in biomedical engineering from Duke University.